Caregiver satisfaction · women with malignant ascites
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cost‐effectiveness · women with malignant ascites
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Menstruation recovery or maintenance: · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy may leads to higher menstruation recovery or maintenance: compared with chemotherapy alone (low certainty).
2 findings from 1 review
Premature ovarian failure · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Pregnancy · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
It is very uncertain whether gnRH agonist‐antagonist cotreatment plus chemotherapy changes pregnancy compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Ovulation · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Adverse events · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Premature ovarian failure · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy probably leads to lower premature ovarian failure compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Pregnancy · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy showed no clear difference in pregnancy compared with chemotherapy alone (low certainty).
1 finding from 1 review
Ovulation · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy may leads to higher ovulation compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse effects: hot flush · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
It is very uncertain whether gnRH agonist plus chemotherapy changes adverse effects: hot flush compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Adverse effects: vaginal dryness · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy showed no clear difference in adverse effects: vaginal dryness compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Menstruation recovery or maintenance: · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
It is very uncertain whether gnRH agonist‐antagonist cotreatment plus chemotherapy changes menstruation recovery or maintenance: compared with chemotherapy alone (very low certainty).
2 findings from 1 review
Risk of invasive ovarian cancer in subfertile women exposed to ovarian stimulating drug vs unexposed women (summary of cohort studies suggesting increased risk) · subfertile women
2 findings from 1 review
Risk of borderline ovarian cancer in subfertile women exposed to ovarian stimulating drugs vs unexposed women (summary of case‐control studies suggesting an increase) · subfertile women
2 findings from 1 review
Treatment failure · Adult patients with cancer who develop a low‐risk febrile neutropaenic event
Outpatients showed no clear difference in treatment failure compared with inpatients ‐ adults (moderate certainty).
1 finding from 1 review
Adverse drug reactions · Children with cancer who develop a low‐risk febrile neutropaenic event
Outpatients showed no clear difference in adverse drug reactions compared with inpatients ‐ children (low certainty).
1 finding from 1 review
Duration of neutropaenia (days) · Children with cancer who develop a low‐risk febrile neutropaenic event
1 finding from 1 review
Length of hospitalisation (days) · Children with cancer who develop a low‐risk febrile neutropaenic event
1 finding from 1 review
Duration of antimicrobial treatment (days) · Children with cancer who develop a low‐risk febrile neutropaenic event
1 finding from 1 review